Int Immunopharmacol (2016) 38:14452
(Removed: "drug") Santus P, Corsico A, Solidoro P, Braido F, Di Marco F, Scichilone N
Instead, it belongs to a unique, dual-action drug class known as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists
Critical uncertainties persist concerning ideal candidate identification, therapeutic sequence, combination strategies with other emerging MASH therapies, long-term durability of benefits, and cost-effectiveness
Is CJC-1295 or Ipamorelin FDA approved